Presentation at Keystone Symposium Highlights Immunitor’s TB Immunotherapies
Presentation details three separate tuberculosis immunotherapies developed by Immunitor in collaboration with academic institutions and private companies in Mongolia, China, Thailand, Ukraine, UK, USA and Canada. Data presented support the Immunitor strategy to target inflammation as the main cause of TB and development of immunomodulators and therapeutic vaccines which demonstrate ability to rapidly clear TB, including MDR-TB and TB with HIV.
Vancouver, BC, Canada (PRWEB) April 02, 2014
Immunitor Inc., announced today that clinical trials’ data encompassing about 2,000 patients in over 30 trials support the immunomodulatory action and therapeutic potential of the company's three immunotherapy products for TB indication: V5, V7 and Immunoxel. These data were detailed in poster presentation at the “Novel Therapeutic Approaches to Tuberculosis” in Keystone, Colorado, USA on the first day of the conference. These immunotherapies are currently being marketed in five countries and further evaluated in licensing clinical trials in additional countries.
In a poster titled, "Clinical experience with immunotherapy regimens in TB patients", Dr. Dmytro Butov, principal investigator of clinical trials, presented data from studies that further characterized the mechanism by which immunotherapies appear to work. Results revealed that immunotherapies have a common effect in suppressing TNF-alpha and stimulating interferon-gamma – events that correlate with beneficial clinical outcome. Even simpler correlates of anti-inflammatory effect that can be easily tested in developing countries were reduced fever, erythrocyte sedimentation rate and lowered leukocyte counts. Thus, effective immune interventions must possess similar if not identical property in terms of anti-inflammatory effect in order to produce clinical improvements observed in Immunitor trials. More importantly, Immunitor’s immunomodulators produced mycobacterial clearance in a as short as one month in over 85% of patients regardless of their baseline status, i.e., drug-sensitive TB, MDR-TB or TB-HIV. In contrast currently used TB drugs require at least 6 months of continuous treatment to cure the disease.
"Data presented at Keystone this week point to increasing recognition of inflammation as playing a critical role in infectious diseases including TB. The supportive data presented this week will allow us to further pursue development of new immunotherapies and we look forward to the possibility for future potential collaborative studies with our peers," said Allen Bain, Ph.D., Director at Immunitor. "We are pleased that our work has attracted an increasing amount of attention among TB researchers and that Immunitor is now seen as a valid partner in this promising new area of TB treatment."
Keystone Symposia serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.
Immunitor Inc., is a biopharmaceutical company dedicated to development of oral immunotherapies, some of which already marketed and others in clinical trials for the treatment and prevention of various diseases, including AIDS, hepatitis, influenza, TB, variety of bacterial and fungal diseases, malaria, atherosclerosis and cancer. Additional information about Immunitor can be found at http://www.immunitor.com.
Dr. Allen Bain
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/04/prweb11720923.htm